diabetestalk.net

What Is Metformin Ir?

Effects Of Metformin Extended Release Compared To Immediate Release Formula On Glycemic Control And Glycemic Variability In Patients With Type 2 Diabetes.

Effects Of Metformin Extended Release Compared To Immediate Release Formula On Glycemic Control And Glycemic Variability In Patients With Type 2 Diabetes.

Abstract PURPOSE: The purpose of this study is to evaluate, in a randomized clinical trial, the effects of metformin immediate release (IR) compared with metformin extended release (XR) on the gastrointestinal tolerability and glycemic control. MATERIALS AND METHODS: We enrolled 253 Caucasian patients with type 2 diabetes not well controlled by diet (glycated hemoglobin [HbA1c] >7.0% and <8.5%). Patients were randomized to metformin IR or metformin XR for a period of 6 months at the maximum tolerated dose. The average dose of metformin IR used was 2,000±1,000 mg/day, while that of metformin XR was 1,000±500 mg/day. We evaluated body weight, HbA1c, fasting and postprandial glucose, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance (HOMA-IR), lipid profile, and levels of some adipocytokines, including tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), visfatin, and vaspin. Moreover, at the baseline and after 6 months, we administered patients some validated questionnaires to assess patients' satisfaction toward treatments. RESULTS: After 6 months, both formulations gave a similar reduction in body weight and body mass index (BMI); however, metformin XR gave a greater improvement in glycemic control, FPI, and HOMA-IR, compared with both baseline and metformin IR. A reduction in total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol was observed with metformin XR compared with IR. Levels of TNF-α, hs-CRP, and vaspin were reduced by metformin XR but not by the IR formulation. Metformin XR also raised the levels of visfatin. CONCLUSION: Metformin XR formulation seems to be more effective than metformin IR in improving glyco-metabolic control, lipid profile, and levels of some adipocytokines in patie Continue reading >>

Metformin Vs Metformin Er

Metformin Vs Metformin Er

I'm seeing quite a few posts on BBSes from people who are having problems with metformin because of side effects that could be eliminated if they were taking the extended release form of this drug. For some reason, many family doctors don't seem to be aware that there is a ER version of this drug that has such benefits. This is probably because metformin is a cheap generic and isn't promoted by herds of beautiful ex-cheerleaders turned drug company salespushers who "educate" doctors about far more expensive--and less effective--newer drugs. Here are the facts: Metformin (also sold under the brand name Glucophage) comes in a regular version which is taken at meal time, three times a day, and an extended release form (marketed as ER or XR) which is taken once a day. Almost always, when people report diarrhea or intense heartburn with metformin, they are taking regular version. I experienced the heartburn on the regular drug. It was very disturbing because the pain was localized over my heart and felt just like the description of a heart attack you read in articles. My doctor assured me it was coming from the metformin, but that didn't make it any easier to live with because I kept wondering how, if I were having a real heart attack, I'd know it wasn't a pain from the drug? The ER version releases the drug more slowly and this usually eliminates the gastrointestinal problems. The trade off with taking the ER form is that the amount of blood sugar lowering you see might be a bit less than with the regular form as the drug acts in a slower smoother fashion rather than hitting all at once. But if you can't take the regular at all drug because of the side effects, the slight weakening in effect is a reasonable trade off. Plus, you only have to remember to take one dose rather Continue reading >>

Metformin Extendedrelease Versus Immediaterelease: An International, Randomized, Doubleblind, Headtohead Trial In Pharmacotherapynave Patients With Type 2 Diabetes

Metformin Extendedrelease Versus Immediaterelease: An International, Randomized, Doubleblind, Headtohead Trial In Pharmacotherapynave Patients With Type 2 Diabetes

Metformin extendedrelease versus immediaterelease: An international, randomized, doubleblind, headtohead trial in pharmacotherapynave patients with type 2 diabetes AAA Clinical Research, Brampton, Ontario, Canada Naresh Aggarwal MD, CCFP, FCFP,AAA Clinical Research, 490 Bramalea Rd, Unit 201, Brampton, ON L6T 0G1, Canada. Email: [email protected] AAA Clinical Research, Brampton, Ontario, Canada Naresh Aggarwal MD, CCFP, FCFP,AAA Clinical Research, 490 Bramalea Rd, Unit 201, Brampton, ON L6T 0G1, Canada. Email: [email protected] Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of Use. Use the link below to share a full-text version of this article with your friends and colleagues. Learn more. This international, randomized, doubleblind trial (NCT01864174) compared the efficacy and safety of metformin extendedrelease (XR) and immediaterelease (IR) in patients with type 2 diabetes. After a 4week placebo leadin, pharmacotherapynave adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive oncedaily metformin XR 2000 mg or twicedaily metformin IR 1000 mg for 24 weeks. The primary endpoint was change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24 weeks. Overall, 539 patients were randomized (metformin XR, N = 268; metformin IR, N = 271). Adjusted mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c <7.0% after 24 weeks were similar for XR and IR: 0.93% vs 0.96%; 21.1 vs 20.6 mg/dL (1.2 vs 1.1 mmol/L); 24.7 vs 27.1 mg/dL (1.4 vs 1.5 mmol/L); and 70.9% vs 72.0%, respectively. Adver Continue reading >>

Evaluation Of Metformin Xr Vs Metformin Ir In Monotherapy In T2dm

Evaluation Of Metformin Xr Vs Metformin Ir In Monotherapy In T2dm

Evaluation of metformin XR vs metformin IR in monotherapy in T2DM A 24-Week International, Multi-centre, Randomised, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise A study to determine if therapy with Metformin Extended Release is as effective and safe as therapy with Metformin Immediate Release. This study is open to adult patients over the age of 18 who have Type 2 Diabetes Mellitus (T2DM) and have inadequate glycaemic control (the amount of sugar in the blood) using just diet and exercise. Metformin is the most common oral medicine given in addition to diet and exercise for blood sugar control in patients with T2DM in the US and the UK. Metformin is available by prescription as an extended release form, which is taken once a day, and as an immediate release form taken 2 to 3 times a day. The 2 treatment regimens are: Metformin Extended Release 2000 mg taken once daily Metformin Immediate release 2000 mg taken as 1000mg twice daily Patients will be randomly allocated to one of the two treatment groups. Patients are planned to attend the study centre for 10 visits over approximately 29 weeks. Patients will have blood and urine collected during study visits and 1 electrocardiogram (ECG) will be performed during the study. Patients will also be asked to self-monitor their blood sugar levels at home using a glucometer which will be provided. This is a multicentre study which will take place globally. It is anticipated that approximately 1048 patients will be asked to take part in the study and that 524 will take part in the treatment phase of this study at about 140 study clinics wor Continue reading >>

Support Article

Support Article

As you were browsing PracticeUpdate, something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled JavaScript in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing JavaScript from running. Additional information is available in this . After completing the CAPTCHA below, you will immediately regain access to PracticeUpdate. ​ You reached this page when attempting to access from 35.184.106.120 on 2018-01-11 11:59:14 UTC. Trace: 2df9f229-771d-47ce-ac52-4155696019af via 0894b646-a920-4bbe-adae-63c4b22043a0 Continue reading >>

Efficacy | Saxagliptin 5 Mg + Metformin Ir Initial Therapy | A1c Levels

Efficacy | Saxagliptin 5 Mg + Metformin Ir Initial Therapy | A1c Levels

Important Safety Information for KOMBIGLYZE XR Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL. Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. If lactic acidosis is suspected, discontinue KOMBIGLYZE XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. Severe renal impairment (eGFR below 30 mL/min/1.73 m2) Prior serious hypersensitivity reaction to saxagliptin or hypersensitivity to metformin hydrochloride Metabolic acidosis, including diabetic ketoacidosis Pancreatitis: There have been post-marketing reports of acute pancreatitis in patients taking saxagliptin, and in the SAVOR cardiovascular outcomes trial. Observe for pancreatitis. If pancreatitis is suspected, discontinue KOMBIGLYZE XR. Heart Failure: In the SAVOR cardiovascular outcomes trial, more patients treated with saxagliptin were hospitalized for heart failure compared to placebo. Patients with a prior history of heart failure or renal impairment had a higher risk for hospitalization for heart failure. Consider the risks and benefits of KOMBIGLYZE XR in patients who have known risk factors Continue reading >>

Dapagliflozin-metformin Tablet, Immediate Release And Extended Release, Biphasic 24hr (tablet,immed & Ext Release,biphasic 24hr)

Dapagliflozin-metformin Tablet, Immediate Release And Extended Release, Biphasic 24hr (tablet,immed & Ext Release,biphasic 24hr)

Headache , diarrhea , nausea , vomiting , runny nose , or sore throat may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. If stomach symptoms return later (after taking the same dose for several days or weeks), tell your doctor right away. Stomach symptoms that occur after the first days of your treatment may be signs of lactic acidosis . An empty tablet shell may appear in your stool. This effect is harmless because your body has already absorbed the medication . Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: signs of a urinary tract infection (such as burning/painful/frequent/urgent urination, pink/bloody urine), signs of kidney problems (such as change in the amount of urine, swelling legs/feet). Use of this medication may result in a new yeast infection in the vagina or penis . You are more likely to get a yeast infection if you have had yeast infections in the genital area before. Uncircumcised men are also at an increased risk for infections. Tell your doctor right away if you have signs of yeast infection in the vagina (such as unusual vaginal discharge /burning/ itching /odor) or in the penis (such as redness/ itching /swelling of the penis, unusual discharge from the penis). Your doctor may direct you to use nonprescription antifungal products to treat these infections. Tell your doctor if your condition persists or worsens after treatment. This medication does not usually cause low blood sugar ( hypoglycemia ). Low blood sugar may occur if this drug is prescribed with oth Continue reading >>

Pay Attention To Your Metformin Hcl Erdiabetes Costs

Pay Attention To Your Metformin Hcl Erdiabetes Costs

Home Drugs To Block Pay Attention to Your Metformin HCL ERDiabetes Costs Pay Attention to Your Metformin HCL ERDiabetes Costs youll likely discover that among your Top 50 Most Expensive Drugs is a line item for generic metformin HCL ER. Metformin HCL is a longstanding, very inexpensive diabetes treatment. And ER stands for extended release. There are metformin HCL ER treatments that are very inexpensive. So the question is: Why would this line item be among your Top 50 most expensive drugs? The answer: There are certain generic forms of metformin HCL ER that are absurdly expensive, while others bear the low-costs that youd expect. But its reasonably likely that many (if not most) of your beneficiaries are unknowingly using the high-cost forms of this drug. To help you understand what is taking place, we provide you with the following Chart, reflecting, first, the immediate release version of metformin, and then the 3 extended release generic versions of this drug. Our 3 columns for each drug identify each of the dosage strengths, the GSN identifiers, and the per unit cost based on current retail Average Acquisition Costs (AACs). Focus in particular on the far right column, reflecting the per unit AACs (reported average retail acquisition costs): Metformin (immediate release): The reference drug is Glucophage: (i) Metformin ER: The reference drug is Glucophage XR: (ii) Metformin OSM: The reference drug is Fortamet: (iii) Metformin ER: The reference drug is Glumetza: As you can see, there are big differences in cost per unit for the generic versions of Fortamet and Glumetza! Thus, its hard to imagine why any entity would cover generic Fortamet and Glumetza products (without at least a very strict letter of medical necessity). Both are examples of generic drugs with gross Continue reading >>

Glucophage Sr 500mg, 750mg And 1000mg Prolonged Release Tablets

Glucophage Sr 500mg, 750mg And 1000mg Prolonged Release Tablets

Glucophage SR 500mg, 750mg and 1000mg prolonged release tablets This information is intended for use by health professionals Glucophage SR 500 mg prolonged release tablets Glucophage SR 750 mg prolonged release tablets Glucophage SR 1000 mg prolonged release tablets 2. Qualitative and quantitative composition 500 mg: One prolonged release tablet contains 500mg metformin hydrochloride corresponding to 390 mg metformin base. 750 mg: One prolonged release tablet contains 750 mg metformin hydrochloride corresponding to 585 mg metformin base. 1000 mg: One prolonged release tablet contains 1000 mg metformin hydrochloride corresponding to 780 mg metformin base. For the full list of excipients, see section 6.1. 500 mg: White to off-white, round, biconvex tablet, debossed on one side with '500'. 750 mg: White capsule-shaped, biconvex tablet, debossed on one side with '750' and on the other side with 'Merck'. 1000 mg: White to off-white capsule-shaped, biconvex tablet, debossed on one side with '1000' and on the other side with 'MERCK'. Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are: - at high risk for developing overt type 2 diabetes mellitus (see section 5.1) and - still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months Treatment with Glucophage SR must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk (see section 5.1). Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons. *IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose Trea Continue reading >>

Metformin Ir Versus Xr Pharmacokinetics In Humans

Metformin Ir Versus Xr Pharmacokinetics In Humans

1University of Petra, Amman, Jordan 2Jordan Center for Pharmaceutical Research (JCPR), Amman, Jordan 3University of Jordan, Amman, Jordan *Corresponding Author: Dr. Nasir Idkaidek University of Petra, Pharmacy College PO Box 961343, Amman, Jordan Tel: 96265715553 Fax: 96265715570 E-mail: [email protected] Citation: Idkaidek N, Arafat T, Melhim M, Alawneh J, Hakooz N (2011) Metformin IR versus XR Pharmacokinetics in Humans. J Bioequiv Availab 3: 233-235. doi: 10.4172/jbb.1000092 Copyright: © 2011 Idkaidek N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Visit for more related articles at Journal of Bioequivalence & Bioavailability Abstract Pharmacokinetics of metformin extended release (XR) formulation were studied under fasting and fed conditions and compared to those of immediate release (IR) under fasting conditions in humans. 78 healthy human volunteers participated in 3 independent studies (26 subjects per study) were given either 1000 mg oral dose metformin IR or 750 mg metformin XR. Plasma samples were obtained up to 24 hours after dosing. Pharmacokinetic parameters in plasma were calculated by non compartmental analysis using Kinetica program. Results have shown increased XR bioavailability and delayed time to reach the maximum concentration (Cmax ) in the fed state as compared to fasted state, with no significant difference in Cmax and half life values. On the other hand, the IR formulation showed significant differences in all parameters as compared to XR formulation, yet the half life was similar. In conclusion, XR formulation was shown similar to IR formulation Continue reading >>

Metformin

Metformin

Metformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes,[4][5] particularly in people who are overweight.[6] It is also used in the treatment of polycystic ovary syndrome.[4] Limited evidence suggests metformin may prevent the cardiovascular disease and cancer complications of diabetes.[7][8] It is not associated with weight gain.[8] It is taken by mouth.[4] Metformin is generally well tolerated.[9] Common side effects include diarrhea, nausea and abdominal pain.[4] It has a low risk of causing low blood sugar.[4] High blood lactic acid level is a concern if the medication is prescribed inappropriately and in overly large doses.[10] It should not be used in those with significant liver disease or kidney problems.[4] While no clear harm comes from use during pregnancy, insulin is generally preferred for gestational diabetes.[4][11] Metformin is in the biguanide class.[4] It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues.[4] Metformin was discovered in 1922.[12] French physician Jean Sterne began study in humans in the 1950s.[12] It was introduced as a medication in France in 1957 and the United States in 1995.[4][13] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[14] Metformin is believed to be the most widely used medication for diabetes which is taken by mouth.[12] It is available as a generic medication.[4] The wholesale price in the developed world is between 0.21 and 5.55 USD per month as of 2014.[15] In the United States, it costs 5 to 25 USD per month.[4] Medical uses[edit] Metformin is primarily used for type 2 diabetes, but is increasingly be Continue reading >>

Fortamet

Fortamet

FORTAMET® (metformin hydrochloride) Extended-Release Tablets DESCRIPTION FORTAMET® (metformin hydrochloride) Extended-Release Tablets contain an oral antihyperglycemic drug used in the management of type 2 diabetes. Metformin hydrochloride (N, Ndimethylimidodicarbonimidic diamide hydrochloride) is a member of the biguanide class of oral antihyperglycemics and is not chemically or pharmacologically related to any other class of oral antihyperglycemic agents. The empirical formula of metformin hydrochloride is C4H11N5•HCl and its molecular weight is 165.63. Its structural formula is: Metformin hydrochloride is a white to off-white crystalline powder that is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. FORTAMET® Extended-Release Tablets are designed for once-a-day oral administration and deliver 500 mg or 1000 mg of metformin hydrochloride. In addition to the active ingredient metformin hydrochloride, each tablet contains the following inactive ingredients: candellila wax, cellulose acetate, hypromellose, magnesium stearate, polyethylene glycols (PEG 400, PEG 8000), polysorbate 80, povidone, sodium lauryl sulfate, synthetic black iron oxides, titanium dioxide, and triacetin. FORTAMET® meets USP Dissolution Test 5. System Components And Performance FORTAMET® was developed as an extended-release formulation of metformin hydrochloride and designed for once-a-day oral administration using the patented single-composition osmotic technology (SCOT™). The tablet is similar in appearance to other film-coated oral administered tablets but it consists of an osmotically active core formulation that is surrounded by a semipermeable membra Continue reading >>

Metformin, Oral Tablet

Metformin, Oral Tablet

Metformin oral tablet is available as both a generic and brand-name drug. Brand names: Glucophage, Glucophage XR, Fortamet, and Glumetza. Metformin is also available as an oral solution but only in the brand-name drug Riomet. Metformin is used to treat high blood sugar levels caused by type 2 diabetes. FDA warning: Lactic acidosis warning This drug has a Black Box Warning. This is the most serious warning from the Food and Drug Administration (FDA). A black box warning alerts doctors and patients to potentially dangerous effects. Lactic acidosis is a rare but serious side effect of this drug. In this condition, lactic acid builds up in your blood. This is a medical emergency that requires treatment in the hospital. Lactic acidosis is fatal in about half of people who develop it. You should stop taking this drug and call your doctor right away or go to the emergency room if you have signs of lactic acidosis. Symptoms include tiredness, weakness, unusual muscle pain, trouble breathing, unusual sleepiness, stomach pains, nausea (or vomiting), dizziness (or lightheadedness), and slow or irregular heart rate. Alcohol use warning: You shouldn’t drink alcohol while taking this drug. Alcohol can affect your blood sugar levels unpredictably and increase your risk of lactic acidosis. Kidney problems warning: If you have moderate to severe kidney problems, you have a higher risk of lactic acidosis. You shouldn’t take this drug. Liver problems warning: Liver disease is a risk factor for lactic acidosis. You shouldn’t take this drug if you have liver problems. Metformin oral tablet is a prescription drug that’s available as the brand name drugs Glucophage, Glucophage XR, Fortamet, and Glumetza. Glucophage is an immediate-release tablet. All of the other brands are extended-r Continue reading >>

Formulation And Evaluation Of Immediate Release Tablets Of Metformin Hydrochloride On Laboratory Scale

Formulation And Evaluation Of Immediate Release Tablets Of Metformin Hydrochloride On Laboratory Scale

Abstract The purpose of this research is to prepare metformin hydrochloride immediate release tablets by wet granulation technique. In order to obtain the best, optimized product ten different formulations were developed. Different binder, disintegrants and lubricants taken as variables. Weight variation, thickness, hardness, friability, disintegration time, in-vitro release and pharmaceutical assay were studied as response variables. Capping was observed in formulation containing PVP K-30. However, in the remaining formulation containing PVP K-90, no capping was observed. The formulation A7 was selected as optimized formulation. The different physical properties and in-vitro release profile showed best comparable with the reference product. Optimization has proven an effective tool in product development. Discover the world's research 14+ million members 100+ million publications 700k+ research projects Join for free granulation technique. In order to obtain the best, optimized product ten different formulations were thickness, hardness, friability, disintegration time, in-vitro release and pharmaceutical assay were showed best comparable with the reference product. Optimization has proven an effective tool in Sodium starch glycolate -- -- 20 -- -- -- -- -- -- -- Povidone k-30 30 30 30 30 30 -- -- Povidone k-90 -- -- -- -- -- 30 40 40 40 40 Sodium stearyl fumarate -- -- -- -- -- -- -- 8 -- 16 30 71.6 70.20 70.8 76.1 80.2 80.1 80.9 76.7 74 71.6 80.1 45 76.7 73.5 75.8 79.6 81.3 82.8 83.8 80.2 75.6 73.8 83.8 60 82.9 78.4 78.3 80.2 83.4 84.4 86.7 81.3 78.2 77.3 89.3 Continue reading >>

Metformin Extended Versus Immediate Release In Saudi Arabia: A Cost-effectiveness Analysis

Metformin Extended Versus Immediate Release In Saudi Arabia: A Cost-effectiveness Analysis

Metformin extended release (XR) has higher treatment adherence than immediate release (IR) formulation, due to lower pill burden and better gastrointestinal tolerability, leading to better glycated hemoglobin (HbA1c) levels control. This study aimed to compare metformin XR versus metformin IR monotherapy for type 2 diabetes mellitus (T2DM) considering the long-term cost-effectiveness outcomes. To access this article, please choose from the options below Continue reading >>

More in diabetes